Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

TB-500 Administration Routes Comparison

Understanding the practical differences between administration routes clarifies why researchers and clinicians universally favor subcutaneous injection for TB-500. The table below compares bioavailability, onset characteristics, technical requirements, and pro

This comparison does not assign a generated winner or score.

  • Understanding the practical differences between administration routes clarifies why researchers and clinicians universally favor subcutaneous injection for TB-500. The table below compares bioavailability, onset characteristics, technical requirements, and professional assessment across the primary routes.
  • Subcutaneous Injection
  • 80–95%
  • 15–30 minutes, peak plasma at 2–4 hours
  • Moderate. Requires sterile technique, bacteriostatic water reconstitution, insulin syringe
  • Lyophilised powder stored −20°C; reconstituted solution refrigerated 2–8°C, use within 28 days
  • Gold standard. Only route with documented systemic activity and peer-reviewed efficacy data
  • Intravenous Injection
  • ~100%
  • Immediate, peak plasma within minutes
  • High. Requires IV access, controlled infusion, medical oversight
  • Same as subcutaneous
  • Research/clinical setting only. Not practical for routine use, no bioavailability advantage over subcutaneous
  • Oral Capsule/Tablet
  • <2% (functionally zero)
  • None. Degraded in stomach before absorption
  • None. Consumer convenience
  • Room temperature stable if encapsulated, no reconstitution
  • Not viable. No detectable plasma levels, mechanism of action requires intact peptide in circulation
  • Intranasal Spray
  • 5–15% (unmodified peptides)
  • 10–20 minutes if absorbed
  • Low. Simple spray application
  • Requires solution formulation, refrigeration recommended
  • Marginal. Insufficient data for TB-500 specifically, absorption through nasal mucosa limited by molecular weight
  • The comparison makes the issue clear: when you take TB-500 orally, you're not choosing a less efficient version of the same delivery. You're choosing a route that doesn't deliver the compound at all.
More references

Related material